Author: Business Wire

La FDA accorde au satralizumab de Chugai la désignation de thérapie novatrice pour le traitement de la neuromyélite optique et des maladies du spectre de la neuromyélite optique

TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé que l’Agence américaine des produits alimentaires et médicamenteux (Food and Drug Administration, FDA) a octroyé la désignation de thérapie novatrice à l’anticorps de recyclage humanisé anti-récepteur de l’interleukine-6 (IL-6) de Chugai, le satralizumab, un médicament expérimental pour le traitement de la neuromyélite optique et des maladies du spectre de la neuromyélite optique (NMO/NMOSD). « Le satralizumab est

Ophthalmic Ultrasound Systems Markets with Forecasts from 2018 to 2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Ultrasound Systems Market – Forecasts From 2018 to 2023” report has been added to ResearchAndMarkets.com’s offering. The global ophthalmic ultrasound systems market is expected to reach US$3.167 billion by 2023 from US$2.008 billion in 2017 growing at a CAGR of 7.89%. The market is expected to show a significant growth during the given forecast period. The growth may be attributed to the increasing prevalence of the eye diseases needing ophthalmic ultras

Global Ocular Inflammation Treatment Market (2019-2023) is Expected to Grow at a CAGR of More Than 6% – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Ocular Inflammation Treatment Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. The ocular inflammation treatment market will register a CAGR of more than 6% by 2023. The technological advances in drug delivery to push growth in the market. The increasing need for novel drug delivery systems has led to the advent of intravitreal implants, which are small hair-stranded sized devices that are implanted into the middle layer of the e

Ophthalmics – Global Partnering Report (2012-2018): Updated Deal Trends, Players and Financials – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Ophthalmics Partnering 2012-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering. Global Ophthalmics Partnering 2012 to 2018 provides the full collection of Ophthalmics disease deals signed between the world’s pharmaceutical and biotechnology companies since 2012. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology.

Intraocular Lens Market – Global Forecasts from 2018 to 2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Intraocular Lens Market – Forecasts From 2018 to 2023” report has been added to ResearchAndMarkets.com’s offering. The Intraocular lens market is projected to grow at a CAGR of 5.98% to reach US$14.759 billion by 2023, from US$10.416 billion in 2017. Growing prevalence of eye diseases like cataracts and increase in initiatives taken by the government to eliminate avoidable blindness are expected to fuel the growth of the intraocular lens market. According to World

Ophthalmology Disease & Epidemiology Overview 2018 Featuring Alimera Sciences, Allergan, Regeneron, Bayer, Santen, Roche, Genentech, & Novartis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ophthalmology – Disease & Epidemiology Overview” report from Decision Resources Group has been added to ResearchAndMarkets.com’s offering. This report provides a disease market overview for each indication and global epidemiology overviews for each indication. The Ophthalmology Disease & Epidemiology Overview report provides disease market overviews and global epidemiology overviews for 4 indications in the Ophthalmology therapy area: Diabetic Macular Edema

Retinopathy of Prematurity – 2018 Pipeline Insight Featuring Biomar Microbial Technologies, F. Hoffmann-La Roche, Recordati, Radikal Therapeutics, EyeGene, and Insmed – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Retinopathy of Prematurity – Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Retinopathy of Prematurity development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by development

Anterior Uveitis – Pipeline Insight, 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Anterior Uveitis – Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Anterior Uveitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated

Rhino-Conjunctivitis – Pipeline Insight, 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Rhino-Conjunctivitis – Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Rhino-Conjunctivitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, as